Pfizer (PFE) Financials
Pfizer (PFE) Historical Financial Statements and Key Metrics for 1994 - 2026
Full Pfizer financials for 1994 - 2026 are available in the
US Historical Financials dataset
All financial data is sourced direct from SEC 10-Q and 10-K filings, restatements are included.
Pfizer Income Statements
(in $ 000,000's)
| Quarter End | Revenue | Gross Profit | Operating Income | Net Income | EBITDA | EPS |
| 2026-Mar-29 | 14,451 | 9,720 (67.3 %) | 4,032 (27.9 %) | 2,688 (18.6 %) | 5,215 | 0.47 |
| 2025-Dec-31 | 17,557 | 12,285 (70.0 %) | 3,688 (21.0 %) | -1,648 (-9.4 %) | 756 | -0.29 |
| 2025-Sep-28 | 16,654 | 12,482 (74.9 %) | 3,550 (21.3 %) | 3,541 (21.3 %) | 5,648 | 0.62 |
| 2025-Jun-29 | 14,653 | 9,420 (64.3 %) | 3,575 (24.4 %) | 2,910 (19.9 %) | 5,323 | 0.51 |
| 2025-Mar-29 | 13,715 | 10,870 (79.3 %) | 4,425 (32.3 %) | 2,967 (21.6 %) | 5,057 | 0.52 |
| 2024-Dec-31 | 17,763 | 11,854 (66.7 %) | 3,187 (17.9 %) | 410 (2.3 %) | 2,520 | 0.07 |
| 2024-Sep-29 | 17,702 | 11,127 (62.9 %) | 5,284 (29.8 %) | 4,465 (25.2 %) | 7,253 | 0.78 |
Full historical income statements for 1994 - 2026 is included in the
US Historical Financials dataset.
Pfizer Balance Sheets
(in $ 000,000's)
| Quarter End | Total Assets | Total Liabilities | Total Debt | Total Equity | Cash & Equivalents |
| 2026-Mar-29 | 207,618 | 117,214 | 64,455 | 90,101 | 13,075 |
| 2025-Dec-31 | 208,160 | 121,385 | 67,416 | 86,476 | 13,596 |
| 2025-Sep-28 | 208,731 | 115,635 | 61,712 | 92,801 | 14,984 |
| 2025-Jun-29 | 206,095 | 117,083 | 61,797 | 88,695 | 13,249 |
| 2025-Mar-29 | 208,028 | 117,391 | 61,291 | 90,338 | 17,316 |
| 2024-Dec-31 | 213,396 | 124,899 | 63,649 | 88,203 | 20,477 |
| 2024-Sep-29 | 219,476 | 126,918 | 66,617 | 92,286 | 9,952 |
Full historical balance sheet data for 1994 - 2026 is included in the
US Historical Financials dataset.
Pfizer Cash Flow Statements
(in $ 000,000's)
| Quarter End | Operating Cash Flow | Investing | Financing | Free Cash Flow |
| 2026-Mar-29 | 2,615 | 785 | -2,856 | 2,179 |
| 2025-Dec-31 | 5,349 | -6,146 | 596 | 4,504 |
| 2025-Sep-28 | 4,603 | -2,430 | -2,476 | 4,001 |
| 2025-Jun-29 | -582 | 3,951 | -3,196 | -1,200 |
| 2025-Mar-29 | 2,335 | 3,274 | -5,227 | 1,771 |
| 2024-Dec-31 | 6,721 | -1,623 | -5,114 | 5,804 |
| 2024-Sep-29 | 6,714 | -2,057 | -4,636 | 6,063 |
Full historical cash flow data for 1994 - 2026 is included in the
US Historical Financials dataset.
Pfizer Key Valuation and Operating Metrics
| Quarter End | Market Capitalization ($ 000,000's) |
Enterprise Value ($ 000,000's) |
Price/Earnings ($ 000,000's) |
Price/Sales ($ 000,000's) |
Price/Book ($ 000,000's) |
| 2026-Mar-29 | 158,039 | 220,791 | 10.94 | 14.70 | 1.75 |
| 2025-Dec-31 | 141,501 | 207,775 | 8.06 | -21.47 | 1.64 |
| 2025-Sep-28 | 135,587 | 195,956 | 8.14 | 9.57 | 1.46 |
| 2025-Jun-29 | 137,804 | 197,963 | 9.40 | 11.84 | 1.55 |
| 2025-Mar-29 | 143,804 | 203,666 | 10.49 | 12.12 | 1.59 |
| 2024-Dec-31 | 150,346 | 212,952 | 8.46 | 91.67 | 1.70 |
| 2024-Sep-29 | 164,003 | 229,528 | 9.26 | 9.18 | 1.78 |
Full historical valuation and operating metrics for 1994 - 2026 are included in the
US Historical Financials dataset.